drugset / Trial / NCT01539590
Study to Evaluate the Safety and Activity of BB3 to Treat Heart Attack
Phase 2
Terminated
5 enrolled
Angion Biomedica Corp
National Heart, Lung, and Blood Institute (NHLBI) · collab
RandomizedParallel-groupQuadruple-blindTreatment
Summary
The study will evaluate the effect of BB3 to preserve myocardial (heart) tissue and function following myocardial infarction (heart attack).
Timeline
- Start
- 2012-07
- Primary completion
- 2013-07
- Completion
- 2013-11
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | BB3 | Small molecule | 2 mg/kg | Intravenous |